Written by .Merck & Co.’s long-running initiative to land a strike on little cell lung cancer (SCLC) has acquired a small triumph. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd) revealed potential in the setting, providing motivation as a late-stage test advances.SCLC is one of the growth styles where Merck’s Keytruda fell short, leading the […]
